20 Dec, EOD - Indian

SENSEX 78041.59 (-1.49)

Nifty 50 23587.5 (-1.52)

Nifty Bank 50759.2 (-1.58)

Nifty IT 43771.05 (-2.63)

Nifty Midcap 100 56906.75 (-2.82)

Nifty Next 50 68702.65 (-2.72)

Nifty Pharma 22501.85 (-0.86)

Nifty Smallcap 100 18714.3 (-2.19)

20 Dec, EOD - Global

NIKKEI 225 38701.9 (-0.29)

HANG SENG 19720.7 (-0.16)

S&P 6008.5 (1.05)

Login/Signup

You are Here : Home > Research

23-Jan-2024

Cipla

NP up 31.83%

'For the quarter ending Dec 2023, consolidated Net sales (including other operating income) of Cipla has increased 13.66% to Rs 6603.81 crore compared to quarter ended Dec 2022.  Sales of Phamaceuticals segment has gone up 13.89% to Rs 6,365.06 crore (accounting for 95.78% of total sales).  Sales of New Ventures segment has gone down 10.17% to Rs 280.51 crore (accounting for 4.22% of total sales).  Inter-segment sales came down from Rs 91.04 crore to Rs 41.76 crore.  

Profit before interest, tax and other unallocable items (PBIT) has jumped 35.91% to Rs 1,698.73 crore.  PBIT of Phamaceuticals segment rose 35.58% to Rs 1,705.59 crore (accounting for 100.40% of total PBIT).  PBIT of New Ventures segment rose 15.93% to Rs -6.86 crore (accounting for -0.40% of total PBIT).  

PBIT margin of Phamaceuticals segment rose from 22.51% to 26.80%.  PBIT margin of New Ventures segment rose from negat...



Pleaselogin & subscribe to view the full report.

More Reports
More Reports View Company Information

  • Results-Analysis   (30-Oct-2024)

    Cipla

    NP up 15.18%

  • Results-Analysis   (27-Jul-2024)

    Cipla

    OP increased 14.85%

  • Results-Analysis   (13-May-2024)

    Cipla

    OP up 12.11%

  • Results-Analysis   (23-Jan-2024)

    Cipla

    NP up 31.83%